Guest: Ted L. Anderson, MD, PhD, FACOG, FACS

Guest: Ethan N. Goldstein, MD, FACOG

Each year there are more than 2.5 million visits to gynecologists for the evaluation of abnormal uterine bleeding in reproductive age and post-menopausal women. The impact of AUB on a patients’ quality of life can range from mild to severe and the importance of effective clinical care cannot be overestimated. Determination of the extent and severity of AUB symptoms can be difficult, therefore the evaluation of the uterus is an integral component in this process. Join Dr. Ted Anderson and Dr. Ethan Goldstein as they discuss the importance of direct visualization of the uterine cavity in establishing the likely cause of AUB, how to interpret the findings of diagnostic hysteroscopy and review the benefits of in-office diagnostic hysteroscopy in the health care delivery system.

Guest: Vishala Neppalli, MD

In this segment, Dr. Vishala Neppalli discusses the importance of a peripheral blood smear review in addition to the clues obtained from both “Red Cell” morphology and “White Blood Cell” morphology and counts. This activity is part of a series of in-depth discussions with oncology thought leaders from the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians. This series was made possible through the generous support of BlueCross BlueShield of Western New York.

Guest: Gal Shafirstein, D.Sc.

In this segment, Dr. Shafirstein describes photodynamic therapy and how it is administered. He also discusses when to consider PDT in lung cancer and being aware of the future application of PDT in head and neck cancer. This activity is part of a series of in-depth discussions with oncology thought leaders from the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians. This series was made possible through the generous support of BlueCross BlueShield of Western New York.

Guest: Amy Allen Case, MD, FAAHPM

In this segment, Dr. Case describes supportive and palliative care and how that differs from hospice/end-of life care. This activity is part of a series of in-depth discussions with oncology thought leaders from the Roswell Park Comprehensive Cancer Center in Buffalo, New York targeting primary care and family physicians. This series was made possible through the generous support of BlueCross BlueShield of Western New York.

Host: Shira Johnson, MD

Guest: Gregory P. Cosgrove, MD, FCCP

Guest: Sonye K. Danoff, MD, PhD

Guest: Christina Garcia, MD, PhD

Guest: Victor J. Thannickal, MD

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias, accounting for as many as 40,000 deaths per year in the United States. There is no cure for IPF, and although two recently approved drugs have been shown to delay progression, prognosis remains poor, with an estimated median survival of about 4 years. Recent research into the genetics and the pathophysiology of the disease has identified a number of potential therapeutic targets that offer hope for improving the management – and potentially for preventing – the disease. The availability of a nationwide Clinical Care Network focused on IPF and the launch of a patient registry are other developments that have improved the outlook for patients and their caregivers. Clinicians would benefit from hearing summaries of scientific presentations by leading experts in IPF from the recent Pulmonary Fibrosis Foundation's PFF Summit.

Host: Lee Philip Shulman, MD, FACOG, FACMG

Guest: Andrew M. Kaunitz, MD, FACOG

Guest: Anita L. Nelson, MD

The negative consequences of an unplanned pregnancy are numerous. For one, there may be maternal or child health issues to consider. Also, an unplanned pregnancy often comes with questions surroundings one’s ability to pursue a job, or education and economic consequences can be tremendous. An unplanned pregnancy often leads the woman or the couple to have to make difficult decisions about abortion, or relationships status. For all these reasons, contraception is integral to the health and well-being of women of childbearing age.

Host: Shira Johnson, MD

Guest: Gregory P. Cosgrove, MD, FCCP

Guest: Sonye K. Danoff, MD, PhD

Guest: Christina Garcia, MD, PhD

Guest: Victor J. Thannickal, MD

Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial pneumonias, accounting for as many as 40,000 deaths per year in the United States. There is no cure for IPF, and although two recently approved drugs have been shown to delay progression, prognosis remains poor, with an estimated median survival of about 4 years. Recent research into the genetics and the pathophysiology of the disease has identified a number of potential therapeutic targets that offer hope for improving the management – and potentially for preventing – the disease. The availability of a nationwide Clinical Care Network focused on IPF and the launch of a patient registry are other developments that have improved the outlook for patients and their caregivers. Clinicians would benefit from hearing summaries of scientific presentations by leading experts in IPF from the recent Pulmonary Fibrosis Foundation Summit.

Host: John J. Russell, MD

Guest: Warner K. Huh, MD

Dr. John Russell and Dr. Warner K. Huh will address questions frequently asked by clinicians and their patients regarding HPV and cervical cancer screening within the context of new US and global screening guidelines.

Guest: Scott Newsome, DO, MSCS, FAAN

The complexity and heterogeneity of multiple sclerosis (MS) pathogenesis renders its clinical course and response to therapy highly variable, particularly among special populations. This includes patients considering pregnancy or minority patients. This necessitates optimal strategies to personalize therapy and monitor disease activity and progression in special populations. This educational activity will review cutting-edge research on the unique considerations for prognosis, monitoring, and treatment response in special populations of MS patients. Focused attention will be given to translating research into optimized therapeutic strategies tailored to patient-specific characteristics with the goal of slowing disease progression. A compelling case study will be presented to illustrate clinically relevant challenges in disease management. Fee Information & Refund/Cancellation Policy:There is no fee for this educational activity. To download the slide handouts for this presentation, please click here.

Host: Andrew Wilner, MD

Guest: Merle Diamond, MD

Treating primary headache disorders can frustrate patients and confound their physicians. However, science is catching up. We'll explore the complexity of the condition and the promise of new therapeutic approaches in an interactive update led by expert faculty: Merle L. Diamond, MD, with host Andrew Wilner, MD.